0000000001111863

AUTHOR

Lionel Piroth

showing 65 related works from this author

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

2015

EA Pôle MERS Hors CT hors EJ; International audience; Background & Aims: To compare the management of chronic hepatitis B (CHB) and its evolution over time in currently followed HIV-positive and HIV-negative patients. Methods: A total of 709 consecutive patients with past or present positive HBs antigenemia seen in October 2012 in 19 French participating centres were included. The data were retrospectively collected from the first visit onwards through standardized questionnaires. Results: Chronic hepatitis B was less often assessed in the 299 HIV-positive patients, who were older, more likely to be male, excessive alcohol drinkers and HBe antigen-, HCV- and HDV-positive. They were also fol…

Liver CirrhosisMale[SDE] Environmental SciencesCirrhosis[SDV]Life Sciences [q-bio]HIV InfectionsComorbidityCohort Studies0302 clinical medicineReference ValuesHIV SeropositivityHBV[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHIV SeronegativityLiver NeoplasmsLamivudinevirus diseasesEntecavirhepatocellular carcinomaMiddle Aged3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeLamivudineHepatocellular carcinoma[SDE]Environmental SciencesDisease ProgressionFemale030211 gastroenterology & hepatologyFranceCohort studymedicine.drugAdultmedicine.medical_specialtyGuanineAntiviral AgentsRisk AssessmentStatistics Nonparametric03 medical and health sciencesHepatitis B ChronicHIV SeronegativityInternal medicinemedicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySurvival analysisRetrospective StudiesHepatitis B Surface AntigensHepatologybusiness.industrycirrhosisHIVmedicine.diseaseSurvival AnalysisComorbiditytenofovirLogistic ModelsMultivariate AnalysisImmunologybusinessentecavir
researchProduct

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretrovira…

2015

OBJECTIVE We explored the impact of lifelong cumulative HIV viremia on immunological recovery during antiretroviral therapy, according to the timing of treatment initiation. METHODS We estimated lifelong cumulative HIV viremia in patients followed in the ANRS PRIMO cohort since primary infection, including 244 patients who started treatment during PHI and had at least one treatment interruption, and 218 patients who started treatment later but with no interruptions. The impact of cumulative viremia on current immunological status was analysed using linear and logistic regression models. RESULTS At the last visit on treatment, median CD4 cell count was 645 cells/μl in the early/intermittent …

AdultCD4-Positive T-LymphocytesMalePercentilemedicine.medical_specialtyTime FactorsImmunologyCD4-CD8 RatioHuman immunodeficiency virus (HIV)CD4-CD8 RatioHIV InfectionsViremiaCD8-Positive T-Lymphocytesmedicine.disease_causeLogistic regressionMedication AdherenceCohort StudiesAntiretroviral Therapy Highly ActiveInternal medicineSecondary PreventionmedicineHumansImmunology and AllergyLongitudinal StudiesProspective StudiesViremiaCd4 cell countbusiness.industrymedicine.diseaseAntiretroviral therapyCD4 Lymphocyte CountInfectious DiseasesAnti-Retroviral AgentsCohortImmunologyFemalebusinessAIDS
researchProduct

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort

2017

BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infecte…

medicine.medical_specialtyHepatitis C virusMedicine (miscellaneous)Binge drinkingmedicine.disease_causeUnit of alcohol03 medical and health sciences0302 clinical medicinePegylated interferonInternal medicinemedicine030212 general & internal medicineProspective cohort studybiologybusiness.industryvirus diseasesHepatitis Cmedicine.diseasebiology.organism_classificationVirologydigestive system diseases3. Good healthPsychiatry and Mental healthCohort030211 gastroenterology & hepatologyCannabisbusinessmedicine.drugAddiction
researchProduct

High Plasma Concentration of Non-Esterified Polyunsaturated Fatty Acids Is a Specific Feature of Severe COVID-19 Pneumonia

2020

Background: The pathogenesis of severe COVID-19 is frequently associated with an uncontrolled inflammatory response. Severe forms of COVID-19 appear to be more frequent in obese patients, but an association with metabolic disorders is not established. Here, we focused on lipoprotein metabolism in patients hospitalized for severe pneumonia, depending on COVID-19 status. Methods: Thirty-four non-COVID-19 and 27 COVID-19 patients with severe pneumonia were enrolled. Most of them required intensive care. Plasma lipid levels, lipoprotein metabolism, and clinical and biological features were assessed. Findings: Despite similar initial metabolic comorbidities and respiratory severity, COVID-19 pat…

chemistry.chemical_classificationApolipoprotein Emedicine.medical_specialtybusiness.industrymedicine.diseaseSepsisPneumoniaNEFAchemistryInternal medicineIntensive caremedicinebusinessBody mass indexLipoproteinPolyunsaturated fatty acidSSRN Electronic Journal
researchProduct

Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

2011

Summary Nearly three-quarters of human immunodeficiency virus–hepatitis C virus (HIV-HCV) coinfected patients in France currently need to be cured of their chronic HCV infection. The increase in sustained virological response rates obtained with the recently available HCV protease inhibitors in treatment-naive genotype-1 patients has generated considerable hope in these co-infected patients. However, several particularities (such as a higher baseline HCV load, more advanced liver fibrosis, frequent co-morbidities, and the risk of toxicity and drug–drug interactions) have not allowed the direct extrapolation of the results observed in HCV-monoinfected patients to patients with HIV-HCV co-inf…

medicine.medical_specialtyHepatitis C virusHuman immunodeficiency virus (HIV)HIV InfectionsContext (language use)medicine.disease_causeAntiviral AgentsViruschemistry.chemical_compoundPegylated interferonFibrosismedicineHumansIntensive care medicineHepatologybusiness.industryRibavirinGastroenterologyvirus diseasesHepatitis C Chronicmedicine.diseasechemistryImmunologyToxicitybusinessAlgorithmsmedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 …

2020

International audience; Background and aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on A…

0301 basic medicineMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatment[SDV]Life Sciences [q-bio]HIV InfectionsLiver transplantationmedicine.disease_causeGastroenterologyAntiviral AgentsCohort Studies03 medical and health sciences0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineCause of DeathmedicineHumansRisk factorComputingMilieux_MISCELLANEOUSHepatologybusiness.industryCoinfectionHazard ratioFatty liverHepatitis C ChronicMiddle Agedmedicine.disease3. Good healthFatty Liver[SDV] Life Sciences [q-bio]030104 developmental biology[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030211 gastroenterology & hepatologyFemaleFranceSteatosisViral hepatitisbusiness
researchProduct

Persistance du risque de décès et d’évènement hépatique après guérison de l’hépatite C chez les patients coinfectés VIH/VHC–cohorte ANRS CO13 Hepavih

2017

Introduction Le risque residuel de deces et d’evenements hepatiques (EH) qui persiste apres la guerison de l’hepatite C, a moyen et long terme, chez le patient co-infecte VIH/VHC est mal connu. Materiels et methodes Au sein d’une cohorte national de patients co-infectes VIH/VHC, nous avons inclus les patients traites pour le VHC et ayant une reponse virologique soutenue (RVS) 3 mois apres la fin du traitement ainsi qu’un resultat disponible de Fibroscan ® (taux d’elastometrie (TE)) realise apres le debut du traitement. Les EH etudies sont : cirrhose decompensee, transplantation hepatique et carcinome hepato-cellulaire (CHC). Ils ont tous ete valides par un comite constitue de cliniciens. Re…

Infectious DiseasesMédecine et Maladies Infectieuses
researchProduct

Isolated Anti-HBc: Significance and Management.

2019

Hepatitis B virus (HBV) infection is prevalent worldwide and is associated with dramatic levels of morbidity and mortality. Isolated anti-HBc (IAHBc) is a particular serological pattern that is commonly found in immunocompromised patients. There is ongoing debate regarding the management of patients with IAHBc. Herein, we summarize the current guidelines and the newest evidence. The frequency of IAHBc is variable, with a higher prevalence in some populations, such as persons living with HIV and others immunocompromised patients. The risk of HBV reactivation depends on host factors (including immunosuppression) and viral factors. It is now well established that immunocompromised patients can…

medicine.medical_specialtyisolated anti-HBc antibodiesmedicine.medical_treatmentHbv reactivationHBV reactivationlcsh:Medicineviral hepatitisReviewmedicine.disease_causeSerology03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030203 arthritis & rheumatologyHepatitis B virusimmunosuppressionbusiness.industrylcsh:Rvirus diseasesImmunosuppressionGeneral Medicinemedicine.diseasehepatitis B infectionAnti hbcVaccination030211 gastroenterology & hepatologybusinessViral hepatitismanagementJournal of clinical medicine
researchProduct

The Respect of Recommendations Provided in an International Travelers' Medical Service: Far From the Cup to the Lips

2013

Equipe plutôt EA Pôle MERS CT3 EJ3; Background: It is not clearly known how frequently the recommendations given to travelers are followed, and what factors could encourage compliance with these recommended measures. Methods: Adults consulting at a Medical Department for International Travelers (International Travelers' Medical Services, ITMS) in October and November 2010 were asked to answer a questionnaire before their journey. They were also contacted for a post-travel telephone interview to determine whether they had followed the recommendations regarding vaccinations and malaria prevention, and the reasons for poor or noncompliance with these recommendations. Results A total of 353 tra…

Adultmedicine.medical_specialtyPediatricsMultivariate analysisprévention conseil[SDV]Life Sciences [q-bio]MEDLINEDirective CounselingChemopreventionAntimalarialsRisk FactorsSurveys and QuestionnairesHealth careOutcome Assessment Health CarePreventive Health ServicesMedicineTravel medicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyMedical prescriptionTravelMosquito Netsbusiness.industryVaccinationGeneral MedicineMiddle AgedMalariaTelephone interviewSocioeconomic FactorsFamily medicineChemoprophylaxis[SDE]Environmental SciencesMosquito netPatient ComplianceFemaleFrancebusinesshuman activitiesTravel Medicine
researchProduct

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients

2018

IF 1.307 (2017); International audience; ObjectiveTo assess whether vitamin D supplementation could be associated with a modification of inflammatory markers and bone turnover in HIV-1-infected patients.Patients and methodsPatients who participated in an initial survey in 2010 and who were followed in the same department were included in a new study in 2012. Between 2010 and 2012, vitamin D supplementation was offered to patients presenting with hypovitaminosis D as per appropriate guidelines. Clinical examinations were performed, and fasting blood samples were taken for inflammation and bone marker evaluations.ResultsOf the 263 patients who participated in the 2010 study, 198 were included…

AdultMale0301 basic medicinemedicine.medical_specialtyHypovitaminose DHIV InfectionsInflammationGastroenterologyBone remodeling03 medical and health sciences0302 clinical medicineHypovitaminosisN-terminal telopeptideTraitement antirétroviral[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineVitamin D and neurologyHumansHiv infected patientsLongitudinal StudiesProspective Studies030212 general & internal medicineVitamin DInflammationVitamin d supplementationbusiness.industryHIVHypovitaminosis DVIHMiddle AgedVitamin D Deficiency16. Peace & justice030112 virologyAntiretroviral therapy3. Good healthInfectious DiseasesDietary SupplementsVitamine DFemaleBone Remodelingmedicine.symptombusinessBone markerMédecine et Maladies Infectieuses
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct

Mycotic Aneurysm of Both Internal Iliac Arteries due to Candida albicans.

2013

International audience; : We report the case of a 21-year-old man, with a Candida-related endocarditis causing multiple emboli and bilateral false aneurysms of the internal iliac arteries. As the distal runoff vasculatures of both internal iliac arteries were occluded, these arteries required ligation. Although there were few consequences with the procedure, multiple emboli and recurrence of endocarditis after cardiac surgery led to the patient's death.

Malemedicine.medical_specialtyMultiple emboliMultiple Organ FailureeducationYoung AdultAneurysmFatal Outcome[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRecurrenceCandida albicans[INFO.INFO-IM]Computer Science [cs]/Medical ImagingMedicineEndocarditisHumanscardiovascular diseasesCardiac Surgical ProceduresCandida albicansSubstance Abuse Intravenoushealth care economics and organizationsbiologyEndocarditis[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryCandidiasisGeneral MedicineMycotic aneurysm[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasebiology.organism_classification3. Good healthCardiac surgerySurgeryTreatment OutcomeIliac Aneurysmcardiovascular systemSurgeryRadiologyCardiology and Cardiovascular MedicinebusinessLigationFalse AneurysmsTomography X-Ray ComputedAneurysm InfectedVascular Surgical Procedures
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of &gt;500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylo…

2016

International audience; Objectives - To develop and validate a prediction score, to quantify, within 48 h of Staphylococcus aureus bacteremia (SAB) diagnosis, the risk of IE, and therefore determine priority for urgent echocardiography. Methods - Consecutive adult patients with SAB in 8 French university hospitals between 2009 and 2011 were prospectively enrolled and followed-up 3 months. A predictive model was developed and internally validated using bootstrap procedures. Results - Among the 2008 patients enrolled, 221 (11.0%) had definite IE of whom 39 (17.6%) underwent valve surgery, 25% of them within 6 days of SAB diagnosis. Ten predictors independently associated with IE were used to …

0301 basic medicinemedicine.medical_treatmentBacteremiaHospitals University0302 clinical medicine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInterquartile rangeVertebral osteomyelitis030212 general & internal medicineLongitudinal StudiesProspective StudiesChildbiologyEndocarditisHeartMiddle AgedStaphylococcal InfectionsImplantable cardioverter-defibrillator3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyEchocardiographyInfective endocarditisChild PreschoolPrognostic scoreFranceMeningitisVIRSTA scoreMicrobiology (medical)Adultmedicine.medical_specialtyStaphylococcus aureusAdolescent030106 microbiologyRisk AssessmentDecision Support Techniques03 medical and health sciencesYoung AdultInternal medicinemedicineHumans[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedbusiness.industryC-reactive proteinmedicine.diseaseConfidence intervalSurgeryBacteremiabiology.proteinInfective endocarditisStaphylococcus aureus bacteremiabusiness
researchProduct

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

2019

Background The association between liver stiffness measurements (LSM) and mortality has not been fully described. In particular the effect of LSM on all-cause mortality taking sustained virological response (SVR) into account needs further study. Methods HIV/HCV participants in the French nation-wide, prospective, multicenter ANRS CO13 HEPAVIH cohort, with ≥1 LSM by FibroScan (FS) and a detectable HCV RNA when the first valid FS was performed were included. Cox proportional hazards models with delayed entry were performed to determine factors associated with all-cause mortality. LSM and SVR were considered as time dependent covariates. Results 1,062 patients were included from 2005 to 2015 …

MaleRNA virusesSustained Virologic ResponseMetabolic disordersSocial SciencesHIV InfectionsHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicineImmunodeficiency VirusesRisk FactorsPsychologyAlcohol consumptionProspective Studies030212 general & internal medicineProspective cohort studyPathology and laboratory medicineMultidisciplinaryDeath ratesCoinfectionHepatitis C virusMortality rateQHazard ratioRvirus diseasesHepatitis CMiddle AgedMedical microbiologyAddicts3. Good healthLiverDrug usersVirusesCohortElasticity Imaging TechniquesMedicineFemale030211 gastroenterology & hepatologyFrancePathogensResearch ArticleCohort studyAdultmedicine.medical_specialtyScienceHepatitis C virusLiver fibrosisAddictionGastroenterology and HepatologyAntiviral AgentsMicrobiology03 medical and health sciencesPopulation MetricsInternal medicineRetrovirusesmedicineHumansMortalityLiver diseasesProportional Hazards ModelsNutritionMedicine and health sciencesBiology and life sciencesFlavivirusesPopulation Biologybusiness.industryProportional hazards modelLentivirusOrganismsViral pathogensHIVHepatitis C Chronicmedicine.diseaseHepatitis virusesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessPLOS ONE
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Optimum combination therapy regimens for HIV/HCV infection

2016

HIV-HCV co-infection mostly affects intravenous drug users, in whom prevalence has tended to decrease in recent years, while it has increased in men who have sex with men, with occurrence of acute hepatitis C. Hepatitis C has a poorer prognosis in patients co-infected with HIV, as clinical progression is faster and degree of hepatic fibrosis is greater. However, optimized ARV treatment is clearly associated with slower progression to hepatic complications. Interactions between HCV and HIV drugs are numerous, which underlines the importance of pharmacological advice for HIV-treated patients before they start HCV treatment. In HIV-HCV co-infection, treatment of hepatitis C has to be offered a…

Microbiology (medical)medicine.medical_specialtyCombination therapyHIV InfectionsHepatic ComplicationAntiviral AgentsMicrobiologyMen who have sex with men03 medical and health sciences0302 clinical medicineVirologyInternal medicineGenotypemedicineHumansDrug Interactions030212 general & internal medicineStage (cooking)Coinfectionbusiness.industryvirus diseasesHepatitis Cmedicine.diseaseHepatitis CInfectious DiseasesImmunologyCoinfectionDrug Therapy Combination030211 gastroenterology & hepatologyHepatic fibrosisbusinessExpert Review of Anti-infective Therapy
researchProduct

Prosthetic joint infection caused by Mycobacterium avium complex.

2019

Aged 80 and overMaleProsthesis-Related Infectionsbiologybusiness.industryProsthetic joint infectionGeneral Medicinebiology.organism_classificationMycobacterium avium ComplexMicrobiologyFatal OutcomePositron-Emission TomographyMedicineHumansMycobacterium avium complexHip ProsthesisbusinessMycobacterium avium-intracellulare InfectionQJM : monthly journal of the Association of Physicians
researchProduct

Determinants of high-grade anal intraepithelial lesions in HIV-positive men having sex with men

2018

Background Identifying determinants for histologically proven high-grade anal intraepithelial lesions (hHSIL) in HIV-positive MSM would allow better targeted screening. Methods APACHES is a prospective study of anal HPV and related-lesions in 513 HIV-positive MSM aged ≥35 in six clinics across France. At baseline, participants underwent high resolution anoscopy (HRA) with biopsy of suspicious lesions, preceded by anal swabs for liquid-based cytology, p16/Ki67 immunostaining, and HPV DNA. hHSIL diagnosis was established by histopathological review panel consensus, and determinants assessed by logistic regression. Results Baseline hHSIL prevalence was 10.4% and did not differ significantly by…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryHuman immunodeficiency virus (HIV)medicine.diseasemedicine.disease_causeLogistic regressionlcsh:Infectious and parasitic diseasesLesionInfectious DiseasesVirologyInternal medicineCytologyBiopsymedicinelcsh:RC109-216medicine.symptomProspective cohort studybusinessAscusImmunodeficiencyPapillomavirus Research
researchProduct

A New Prognosis Score to Predict Mortality After Acute Pneumonia in Very Elderly Patients

2016

International audience; Objectives: Acute pneumonia (AP) induces an excess of mortality among the elderly. We evaluated the value of a new predictive biomarker index compared to usual prognosis scores for predicting in-hospital and 1-year mortalities in elderly inpatients with AP.Design: Retrospective study in 6 clinical departments of a university hospital.Setting: Burgundy university hospital (France).Participants: All patients aged 75 and over with AP and hospitalized between January 1 and June 30, 2013, in the departments of medicine (5) and intensive care (1) of our university hospital.Measurements: A new index, which we named UBMo, was created by multiplying the uremia (U in the formu…

Malecommunity-acquired pneumoniaPneumonia severity indexseveritysepsis0302 clinical medicineElderlyadultsscoreHospital Mortality030212 general & internal medicineProspective cohort studyGeneral NursingAged 80 and overvalidation[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyHealth PolicyMortality rateGeneral Medicinecohort3. Good healthAcute DiseaseFemaleFranceterm survivalmanagementmedicine.medical_specialtyhospitalized-patients[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology03 medical and health sciencesPredictive Value of TestsIntensive careInternal medicinemedicineHumanspneumoniaIntensive care medicineAgedRetrospective Studiesbusiness.industrybiomarkersRetrospective cohort studymedicine.diseasemortalityUremiaPneumoniaBlood pressure030228 respiratory systemprognosisGeriatrics and Gerontologybusiness
researchProduct

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infecte…

2018

International audience; BACKGROUND:Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment.METHODS:ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV tr…

RNA virusesMaleHealth BehaviorSocial Scienceslcsh:MedicineHIV InfectionsHepacivirusGeographical locationsChronic Liver Disease0302 clinical medicineRisk FactorsPrevalencePsychologyAlcohol consumptionProspective Studies030212 general & internal medicineYoung adultProspective cohort studylcsh:SciencePathology and laboratory medicinemedia_commonChronic hepatitisDrug injectionClinical Trials as TopicMultidisciplinarybiologyPharmaceuticsCoinfectionHepatitis C virusLiver Diseasesvirus diseasesMedical microbiologyMiddle AgedPrognosisHepatitis CAddicts3. Good healthEuropeBehavioral PharmacologyDrug usersVirusesCohortFemale030211 gastroenterology & hepatologyDrug therapyFrancePathogensResearch ArticleAdultDrugmedicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectLiver fibrosisAddictionContext (language use)Gastroenterology and HepatologyMicrobiologyAntiviral AgentsYoung Adult03 medical and health sciencesPharmacotherapyRecreational Drug UseInternal medicinemedicineHumansEuropean UnionNutritionAgedCannabisMedicine and health sciencesPharmacologyBiology and life sciencesFlavivirusesbusiness.industrylcsh:ROrganismsViral pathogensHIVbiology.organism_classificationHepatitis virusesdigestive system diseasesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologielcsh:Q[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCannabisPeople and placesbusiness
researchProduct

Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in…

2003

We investigated the immune response induced by mucosal immunization of BALB/c mice with virus-like particles (VLPs) of a genogroup II norovirus, Dijon171/96 virus, produced in the baculovirus system. VLPs administered alone by the intranasal route induced a high serum antibody response as well as fecal IgA, which were enhanced when the heat-labile Escherichia coli toxin or its non toxic mutant LT(R192G) was coadministered. In these conditions, the oral route was also efficient. Cytokine production by cells from different lymphoid tissues was then assessed after in vitro restimulation. A Th1/Th2-like response was observed in cervical lymph node and Peyer's patch (PP) cell cultures from mice …

Cellular immunityvirusesmedicine.medical_treatmentAdministration OralEnzyme-Linked Immunosorbent AssayAntibodies ViralBALB/cMicrobiologyFecesMiceTh2 CellsImmune systemAdjuvants ImmunologicVirus-like particlemedicineAnimalsAdministration IntranasalCells CulturedImmunity CellularMice Inbred BALB CVaccines SyntheticGeneral VeterinaryGeneral Immunology and MicrobiologybiologyNorovirusPublic Health Environmental and Occupational HealthViral VaccinesTh1 Cellsbiology.organism_classificationVirologyInfectious DiseasesCytokineAntibody FormationHumoral immunitybiology.proteinMolecular MedicineFemaleLymph NodesAntibodyAdjuvantSpleenVaccine
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Head and neck squamous cell carcinoma in people living with HIV in France.

2018

Abstract Objectives Head and neck squamous cell carcinoma (HNSCC), mainly due to smoking, is one of the leading causes of cancer deaths. However, an increasing number of tumors – especially oropharyngeal cancer – are reported in non-smokers in association with the human papillomavirus (HPV). As HIV-infected individuals are particularly at risk of HPV-related disease, we aimed to describe the burden of HNSCC in this population. Methods Retrospective chart review of patients from HIV clinics diagnosed with HNSCC between 2004 and 2014. Case patients were defined using the International Classification of Disease for Oncology (3rd edition). Age at HIV diagnosis and time from HIV diagnosis to HNS…

LarynxOncologyMalemedicine.medical_specialtyPopulationHuman immunodeficiency virus (HIV)HIV InfectionsDiseasemedicine.disease_causeCauses of cancer03 medical and health sciences0302 clinical medicineInternal medicineotorhinolaryngologic diseasesCarcinomamedicineHumans030212 general & internal medicineeducationLaryngeal NeoplasmsComputingMilieux_MISCELLANEOUSRetrospective Studieseducation.field_of_studyHypopharyngeal Neoplasmsbusiness.industrySquamous Cell Carcinoma of Head and Neckvirus diseasesCancerMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinoma[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthstomatognathic diseasesInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesis[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMouth NeoplasmsFrancebusinessMedecine et maladies infectieuses
researchProduct

Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study

2010

Acute hepatitis C continues to be a concern in men who have sex with men (MSM), and its optimal management has yet to be established. In this study, the clinical, biological, and therapeutic data of 53 human immunodeficiency virus (HIV)-infected MSM included in a multicenter prospective study on acute hepatitis C in 2006-2007 were retrospectively collected and analyzed. The mean hepatitis C virus (HCV) viral load at diagnosis was 5.8 ± 1.1 log10 IU/mL (genotype 4, n = 28; genotype 1, n = 14, genotype 3, n = 7). The cumulative rates of spontaneous HCV clearance were 11.0% and 16.5% 3 and 6 months after diagnosis, respectively. Forty patients were treated, 38 of whom received pegylated interf…

medicine.medical_specialtyHepatologybusiness.industryRibavirinHepatitis C virusvirus diseasesHepatitis CHepatologymedicine.diseasemedicine.disease_causeGastroenterologydigestive system diseasesMen who have sex with menchemistry.chemical_compoundchemistryPegylated interferonInternal medicineImmunologymedicineProspective cohort studybusinessViral loadmedicine.drugHepatology
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels &gt;1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL &gt;20 copies/mL but &lt;1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Cancer and Infective Endocarditis: Characteristics and Prognostic Impact

2021

Background: The interplay between cancer and IE has become of increasing interest. This study sought to assess the prevalence, baseline characteristics, management, and outcomes of IE cancer patients in the ESC EORP EURO-ENDO registry.Methods: Three thousand and eighty-five patients with IE were identified based on the ESC 2015 criteria. Three hundred and fifty-nine (11.6%) IE cancer patients were compared to 2,726 (88.4%) cancer-free IE patients.Results: In cancer patients, IE was mostly community-acquired (74.8%). The most frequently identified microorganisms were S. aureus (25.4%) and Enterococci (23.8%). The most frequent complications were acute renal failure (25.9%), embolic events (2…

medicine.medical_specialtyCardiovascular Medicineregistryvalve diseasesurgeryInternal medicinemedicinecancerDiseases of the circulatory (Cardiovascular) systemOriginal Researchbusiness.industryinfective endocarditisCancermedicine.diseaseCardiac surgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieBaseline characteristicsHeart failureInfective endocarditisRC666-701oncologyCohort[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieObservational studyCardiology and Cardiovascular MedicinebusinessValve diseasecardiac surgeryFrontiers in Cardiovascular Medicine
researchProduct

Staphylococcus aureus bloodstream infection in patients with prosthetic joint included in the prospective VIRSTA cohort study: frequency and time of …

2019

International audience; Among 143 patients of the VIRSTA cohort study with Staphylococcus aureus bacteremia and an arthroplasty implanted for more than a year, S. aureus periprosthetic joint infection was observed in 19%. Signs of infection (pain and swelling) were always present, in median 1 day (range, 0-21 days) after onset of bacteremia. Staphylococcus aureus has both a high potential for metastatic infection and a high affinity for foreign material. Possible prosthesis infection is of clinical concern in all patients with preexisting prosthetic materials experiencing S. aureus bloodstream infection (SAB). Prosthetic joints are especially prone to infection during the course of bacterem…

0301 basic medicinemedicine.medical_specialtyStaphylococcus aureusmedicine.medical_treatment030106 microbiologyPeriprostheticbloodstream infectionmedicine.disease_causeProsthesis03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineprosthetic joint infectionProspective cohort studybusiness.industryBrief Reportmedicine.diseaseArthroplasty3. Good healthInfectious DiseasesOncologyStaphylococcus aureusBacteremiaImplantbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCohort study
researchProduct

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

2021

Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients …

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Critical CareSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralMEDLINElcsh:MedicineLymphocyte ActivationSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingmedicineHumansAgedAged 80 and overInnate immune systembusiness.industrySARS-CoV-2lcsh:RCorrectionCOVID-19General MedicineMiddle Agedmedicine.diseasePrognosisRespiration ArtificialImmunity InnatePneumoniaImmunologyFemaleFrancebusinessJournal of Translational Medicine
researchProduct

Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus–Positive Men Who Have Sex with Men

2018

A correction has been published:The Journal of Infectious Diseases, Volume 218, Issue 8, 15 October 2018, Page 1350, https://doi.org/10.1093/infdis/jiy315; International audience; Background:We assessed prevalence and risk factors for anal human papillomavirus (HPV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM), who are at high-risk of HPV-related anal cancer.Methods:APACHES is a multicentric, prospective study of anal HPV infection and lesions in HIV-positive MSM aged ≥35 years. At baseline, participants underwent anal swabs for HPV and cytology, plus high-resolution anoscopy. High-risk HPV (HR-HPV) was tested by Cobas4800, with genotyping of HR-HPV positiv…

medicine.medical_specialtymen who have sex with menMen who have sex with men03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyAnal cancer030212 general & internal medicineanal canalProspective cohort studyhuman papillomavirusGenotypinghigh-resolution anoscopy[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologymedicine.diagnostic_testhuman immunodeficiency virusbusiness.industryHPV infectionAnoscopyvirus diseasesOdds ratio16. Peace & justicemedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complications3. Good healthInfectious Diseases030220 oncology & carcinogenesisbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Oral delivery of homologous and heterologous strains of rotavirus to BALB/c mice induces the same profile of cytokine production by spleen cells.

1998

Abstract In this work, we wanted to clarify if differences in antibody (Ab) and particularly in secretory immunoglobulin A (IgA) responses following homologous or heterologous rotavirus infection could be explained by different priming of specific T helper (Th) cells. We compared the Ab responses from suckling BALB/c mice orally inoculated with either a heterologous simian (SA11) or bovine (RF) rotavirus or a homologous murine rotavirus (EHP w ), as well as the profile of cytokines produced by spleen cells after in vitro restimulation. Oral inoculation of EHP w and SA11 induced a similar pattern of Ab with mucosal and serum IgA associated with serum IgG with equal levels of IgG1 and IgG2a, …

CD4-Positive T-LymphocytesDiarrheaRotavirusHeterologousAdministration OralSpleenmedicine.disease_causeAntibodies ViralVirus ReplicationRotavirus InfectionsBALB/cInterferon-gammaMiceImmune systemAntigenSpecies SpecificityPregnancyRotavirusVirologymedicineAnimalsMice Inbred BALB CbiologyImmunogenicityHaplorhinibiology.organism_classificationMolecular biologymedicine.anatomical_structureAnimals NewbornImmunoglobulin A Secretorybiology.proteinCytokinesCattleFemaleAntibodyInterleukin-5SpleenVirology
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

2017

International audience

Microbiology (medical)MESH: Antiviral AgentsMESH: Hepatitis B ChronicMEDLINEMESH: Hepatitis B Core AntigensAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicmedicineHumansHepatitis B Vaccines030212 general & internal medicineHepatitis B AntibodiesMESH: Hepatitis B AntibodiesMESH: Hepatitis B VaccinesMESH: Humansbusiness.industryHepatitis Bmedicine.diseaseVirologyHepatitis B Core AntigensHepatitis b core antibodyMESH: DNA ViralInfectious Diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyDNA Viral030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort

2017

International audience; Background & aims: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported.Methods: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational cohort were included if they began an all-oral DAA-based regimen before 1st May 2015 (12-week regimens) or 1st February 2015 (24-week regimens). Treatment success (SVR12) was defined b…

Malemedicine.medical_specialtyHepatitis C virus[SDV]Life Sciences [q-bio]Integrase inhibitorHIV Infectionsmedicine.disease_causeAntiviral AgentsHIV/HCV co-infectionCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineparasitic diseasesmedicineHumans030212 general & internal medicineAdverse effectHepatologyReverse-transcriptase inhibitorbusiness.industryCoinfectionRibavirinvirus diseasesHepatitis C ChronicMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthRegimenSustained virological responseLogistic ModelschemistryImmunologyCohort030211 gastroenterology & hepatologyFemaleAll-oral DAAbusinessCohort studymedicine.drug
researchProduct

Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation

2017

International audience; Pneumonia may involve methicillin-resistant Staphylococcus aureus (MRSA), with elevated rates of antibiotics failure. The present study aimed to assess the effect of statins given prior to pneumonia development. Spontaneously breathing (SB) or mechanically ventilated (MV) rabbits with pneumonia received atorvastatin alone, linezolid (LNZ) alone, or a combination of both (n = 5 in each group). Spontaneously breathing and MV untreated infected animals (n = 11 in each group), as well as uninfected animals (n = 5 in each group) were used as controls. Microbiological features and inflammation were evaluated. Data are presented as medians (interquartile range). Linezolid a…

0301 basic medicinePulmonologyPhysiologymedicine.medical_treatmentAtorvastatinStaphylococcuslcsh:MedicineInduced Lung Injurychemistry.chemical_compound0302 clinical medicineImmune PhysiologyMedicine and Health SciencesAtorvastatinlcsh:ScienceImmune ResponseLungPathology and laboratory medicineMammalsInnate Immune SystemMultidisciplinaryRespirationDrugsEukaryotaAnimal ModelsMedical microbiology3. Good healthBody FluidsUp-Regulationmedicine.anatomical_structureBloodExperimental Organism SystemsBreathingAnesthesiaVertebratesLeporidsCytokinesMethicillin-resistant Staphylococcus aureusRabbitsPathogensAnatomyIn-Vivomedicine.drugResearch Article[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]Staphylococcus aureusStatinmedicine.drug_class030106 microbiologyImmunologyOutcomesResearch and Analysis MethodsMicrobiologySepsis03 medical and health sciencesSigns and SymptomsDiagnostic MedicineSepsismedicinePneumonia BacterialAnimalsTidal-VolumeMortality[ SDV.OT ] Life Sciences [q-bio]/Other [q-bio.OT]Mechanical ventilationPharmacologyInflammationLungBacteriabusiness.industrylcsh:ROrganismsLinezolidStatinsBiology and Life Sciences030208 emergency & critical care medicinePneumoniaMolecular Developmentmedicine.diseaseRespiration ArtificialToll-Like Receptor 2Microbial pathogensPneumoniachemistryBacteremiaImmune SystemLinezolidAmnioteslcsh:QBacterial pathogensbusinessPhysiological ProcessesDevelopmental BiologyModel
researchProduct

Emergence of tularemia in France: paradigm of the Burgundy region

2011

International audience; We report three consecutive cases of tularemia occurring in Burgundy, France, a region previously considered not endemic for tularemia. The patients presented with varied and unspecific clinical manifestations. The epidemiological circumstances, especially the mode of contamination, were not particularly suggestive of tularemia. Serological diagnosis was delayed in two cases because of the lack of significant antibody titers at the time of admission. In contrast, a diagnosis could readily be obtained in all three cases by detection of Francisella tularensis DNA from clinical samples using PCR-based methods. These cases highlight the increased incidence and geographic…

MaleEpidemiologyMESH: Lymph NodesCommunicable Diseases EmergingSerologyTularemia0302 clinical medicineMESH: Early DiagnosisEpidemiologyDiagnosisMESH: Communicable Diseases Emerging030212 general & internal medicineMESH: DoxycyclineFrancisella tularensisTularemia0303 health sciencesMESH: TularemiaMESH: Middle AgedbiologyMESH: Real-Time Polymerase Chain ReactionIncidence (epidemiology)[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Antibody titerGeneral Medicinerespiratory systemMiddle Aged3. Good healthAnti-Bacterial AgentsInfectious DiseasesFrancisella tularensis DNADoxycyclineFemaleFranceFluoroquinolonesAdultDNA BacterialMicrobiology (medical)medicine.medical_specialtyReal-Time Polymerase Chain Reactioncomplex mixtures03 medical and health sciencesMESH: Francisella tularensisMESH: Anti-Bacterial AgentsmedicineHumansFrancisella tularensisMESH: Humans030306 microbiologyMESH: AdultMESH: Fluoroquinolonesbiology.organism_classificationmedicine.diseasebacterial infections and mycosesVirologyMESH: DNA BacterialMESH: MaleMESH: FranceEarly DiagnosisbacteriaLymph NodesMESH: FemaleReal-time PCRInternational Journal of Infectious Diseases
researchProduct

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients

2016

International audience; In hepatitis B “e” antigen (HBeAg) positive patients with hepatitis B virus (HBV) mono-infection, intensification of nucleos(t)ide analogue treatment with pegylated interferon (PegIFN) could help induce higher HBeAg seroclearance rates. Our aim was to determine the long-term effect of adding PegIFN to tenofovir (TDF)-containing antiretroviral therapy on seroclearance in HBeAg-positive patients co-infected with the human immunodeficiency virus (HIV) and HBV. In this prospective matched cohort study, 46 patients with 1-year PegIFN intensification during TDF-containing antiretroviral therapy (TDF+PegIFN) were matched 1:1 to controls undergoing TDF without PegIFN (TDF) u…

AdultMaleHBsAgmedicine.medical_specialtyCirrhosisTenofovirmedicine.disease_causeAntiviral Agents[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyGastroenterology03 medical and health sciencesHepatitis B Chronic0302 clinical medicinePegylated interferonVirologyInternal medicinemedicineHumansHepatitis B e AntigensLongitudinal StudiesProspective Studies030212 general & internal medicineTenofovirProspective cohort studyHepatitis B virusHepatologybusiness.industryvirus diseasesMiddle AgedHepatitis Bmedicine.diseasedigestive system diseases3. Good healthTreatment OutcomeInfectious DiseasesHBeAgImmunology[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyFemale030211 gastroenterology & hepatologyInterferonsbusinessmedicine.drug
researchProduct

Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.

2018

Objective - To assess determinants for histologically proven high-grade anal intraepithelial lesions (hHSIL) in HIV-positive men who have sex with men (MSM), a population at high-risk of HPV-related anal cancer. Design - APACHES is a prospective study of anal HPV and related-lesions in 513 HIV-positive MSM aged at least 35 years in six centres across France. Methods - At baseline, participants underwent high-resolution anoscopy (HRA) with biopsy of suspicious lesions, preceded by anal swabs for liquid-based cytology, p16/Ki67 immunostaining, and HPV DNA. hHSIL diagnosis was established by histopathological review panel consensus, and determinants assessed by logistic regression. Results - B…

AdultMalemedicine.medical_specialtyBiopsyImmunologyPopulationHIV InfectionsMen who have sex with men03 medical and health sciences0302 clinical medicineCytologyInternal medicineBiopsymedicinePrevalenceImmunology and AllergyAnal cancerHumans030212 general & internal medicineProspective StudiesHomosexuality MaleProspective cohort studyeducationAgededucation.field_of_studyHuman papillomavirus 16medicine.diagnostic_testbusiness.industryPapillomavirus InfectionsAnoscopyMiddle Agedmedicine.diseaseAnus Neoplasms3. Good healthInfectious Diseases030220 oncology & carcinogenesisFemaleFranceSquamous Intraepithelial Lesions of the CervixbusinessAscusAIDS (London, England)
researchProduct

Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-l…

2001

ABSTRACTWe investigated the rotavirus-specific lymphocyte responses induced by intranasal immunization of adult BALB/c mice with rotavirus 2/6 virus-like particles (2/6-VLPs) of the bovine RF strain, by assessing the profile of cytokines produced after in vitro restimulation and serum and fecal antibody responses. The cytokines produced by splenic cells were first evaluated. Intranasal immunization with 50 μg of 2/6-VLPs induced a high serum antibody response, including immunoglobulin G1 (IgG1) and IgG2a, a weak fecal antibody response, and a mixed Th1/Th2-like profile of cytokines characterized by gamma interferon and interleukin 10 (IL-10) production and very low levels of IL-2, IL-4, and…

Interleukin 2RotavirusCholera ToxinLymphocyteImmunologyBacterial ToxinsBiologymedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesEnterotoxinsInterferon-gammaMiceImmune systemTh2 CellsAdjuvants ImmunologicVirologyChlorocebus aethiopsmedicineAnimalsInterferon gammaInterleukin 5Administration Intranasal030304 developmental biology[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology0303 health sciencesMice Inbred BALB C030306 microbiologyToxinEscherichia coli ProteinsCholera toxinVirionTh1 Cells3. Good healthVIROLOGIEmedicine.anatomical_structureImmunizationInsect Science[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyImmunologyPathogenesis and ImmunityCytokinesInterleukin-2FemaleImmunizationInterleukin-5medicine.drug
researchProduct

Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

2016

International audience; Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyStaphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsBacteremiaPenicillinsPrognostic factorsTertiary Care Centers03 medical and health sciencesInterquartile range[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinInternal medicineCase fatality ratemedicineHumansBlood cultureProspective StudiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedAntistaphylococcal penicillinsCross Infectionmedicine.diagnostic_testbusiness.industrySeptic shockGeneral MedicineMiddle AgedStaphylococcal Infectionsmedicine.diseasePrognosisSurvival Analysis3. Good healthSurgeryInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinBacteraemiaAntistaphylococcal penicillinFemaleFrancebusinessmedicine.drug
researchProduct

Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

2021

Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support. Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial in adults hospitalised with COVID-19 (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care alone or in combination with intravenous remdesivir (200 mg on day 1, then 100 mg once-daily for 9 days or until discharge). Treatment assignation was performed via web-based randomisation stratified on illness severity and administrative European regio…

education.field_of_studymedicine.medical_specialtybusiness.industryPopulationDeclarationCommissionTreatment and control groupsInformed consentFamily medicineHealth caremedicinemedia_common.cataloged_instanceEuropean unioneducationbusinessPsychology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDeclaration of Helsinkimedia_commonSSRN Electronic Journal
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

2015

The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. HIV/H…

medicine.medical_specialtyHepatitis C virusImmunologyPopulationHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsVirusLiver diseaseChronic hepatitisVirologyInternal medicinemedicineHumansHiv infected patientsDrug Interactionseducationeducation.field_of_studyOncology (nursing)business.industryvirus diseasesHematologyHepatitis C Chronicmedicine.diseasedigestive system diseasesTreatment OutcomeInfectious DiseasesOncologyImmunologyCoinfectionDrug Therapy CombinationbusinessCurrent Opinion in HIV and AIDS
researchProduct

Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia

2021

Rationale: COVID-19 displays distinct characteristics that suggest a unique pathogenesis. The objective of this study was to compare biomarkers of coagulopathy and outcomes in COVID-19 and non-COVID-19 patients with severe pneumonia.Methods: Thirty-six non-COVID-19 and 27 COVID-19 non-immunocompromised patients with severe pneumonia were prospectively enrolled, most requiring intensive care. Clinical and biological characteristics (including plasma biomarkers of coagulopathy) were compared.Results: At similar baseline severity, COVID-19 patients required mechanical ventilation (MV) for significantly longer than non-COVID-19 patients (p = 0.0049) and more frequently developed venous thrombot…

Medicine (General)medicine.medical_specialtymedicine.medical_treatmentVCAM1030204 cardiovascular system & hematologymedicine.disease_causeGastroenterologycoagulopathyPathogenesis03 medical and health sciencesR5-9200302 clinical medicineIntensive careInternal medicinemedicineCoagulopathypneumonia030212 general & internal medicinethrombosisMechanical ventilationbusiness.industryCOVID-19General MedicineImmune dysregulationBrief Research Reportacute respiratory distress syndromemedicine.diseaseThrombosisClinical trialPneumoniaMedicinebusinessFrontiers in Medicine
researchProduct

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV–HIV-coinfected patients receiving ribavirin combined with a first-generati…

2017

Background We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV–HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC). Methods Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (Ctrough) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV Ctrough, response and haematotoxicity (grade 3/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV Ctrough on anaemia…

Malemedicine.medical_specialtyGenotype[SDV]Life Sciences [q-bio]Human immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsGastroenterologychemistry.chemical_compoundPharmacotherapyGene FrequencyRisk FactorsInternal medicineRibavirinmedicineHumansGenetic Predisposition to DiseasePharmacology (medical)PyrophosphatasesAllelesComputingMilieux_MISCELLANEOUSPharmacologyCoinfectionbusiness.industryRibavirinAnemiaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFirst generation3. Good health[SDV] Life Sciences [q-bio]Infectious DiseaseschemistryMutationCoinfectionDrug Therapy CombinationFemaleITPAbusinessMetabolism Inborn ErrorsINOSINE TRIPHOSPHATASE
researchProduct

Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

2010

Background & Aims Recent findings in hepatitis C virus (HCV)-monoinfected patients have shown a correlation between low serum levels of 25-OH vitamin D3 [25(OH)D3] and severe liver fibrosis and low sustained virologic response to therapy. Data are lacking in HIV-HCV coinfected patients. Methods One hundred and eighty nine HIV-HCV coinfected patients, who received ⩾80% of interferon (IFN) plus ribavirin therapy, were analyzed for baseline serum 25(OH)D3 levels. Correlations between serum 25(OH)D3 levels, chronic hepatitis C features, HCV virologic response to antiviral therapy, and HIV infection characteristics were analyzed. Results Mean serum 25(OH)D3 level was 18.5±9.8ng/ml, including 162…

METAVIR Fibrosis ScoreVitaminAdultLiver CirrhosisMalemedicine.medical_specialtyHepatitis C virusHIV Infectionsmedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness Indexchemistry.chemical_compoundInternal medicineAntiretroviral Therapy Highly ActiveSeverity of illnessRibavirinmedicineVitamin D and neurologyPrevalenceHumansVitamin DImmunodeficiencyHepatologybusiness.industryRibavirinInterferon-alphaHepatitis CHepatitis C Chronicmedicine.diseaseVitamin D DeficiencychemistryImmunologyFemaleDrug MonitoringbusinessBiomarkersJournal of hepatology
researchProduct

Staphylococcus aureus Bloodstream Infection and Endocarditis―A Prospective Cohort Study

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu The VIRSTA Study Group : Clinical centres: Besançon: Catherine Chirouze, Elodie Curlier, Cécile Descottes-Genon, Bruno Hoen, Isabelle Patry, Lucie Vettoretti. Dijon: Pascal Chavanet, Jean-Christophe Eicher, Sandrine Gohier-Treuvelot, Marie-Christine Greusard, Catherine Neuwirth, André Péchinot, Lionel Piroth. Lyon: Marie Célard, Catherine Cornu, François Delahaye, Malika Hadid, Pascale Rausch. Montpellier: Audrey Coma, Florence Galtier, Philippe Géraud, Hélène Jean-Pierre, Vincent Le Moing, Catherine Sportouch, Jacques Reynes. Nancy: Nejla Aissa, Thanh Doco- Lecompte, François Goehringer, Nathalie Keil, Lorraine Letranchant, Hepher Malela, Thierry…

AdultMaleStaphylococcus aureuslcsh:MedicineBacteremiaRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesPneumonia Staphylococcal80 and overHumansProspective StudiesHospital Mortalitylcsh:ScienceAgedAged 80 and overEndocarditislcsh:RBacterial[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieEndocarditis BacterialPneumoniaMiddle Aged[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieStaphylococcal[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslcsh:QFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFranceResearch Article
researchProduct

Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study.

2019

ObjectivesTo describe hospitalisations for kidney disease (KD) among people living with HIV (PLHIV) in France and to identify the factors associated with such hospitalisations since data on the epidemiology of KD leading to hospitalisation are globally scarce.DesignObservational nationwide study using the French Programme de Médicalisation des Systèmes d’Information database.SettingFrance 2008–2013.ParticipantsAround 10 862 PLHIV out of a mean of 5 210 856 patients hospitalised each year. All hospital admissions with a main diagnosis code indicating KD (International Classification of Diseases, 10th revision codes, N00 to –N39) were collected.Main outcome measuresThe prevalence and incidenc…

AdultMalemedicine.medical_specialtyPediatricskidney diseasePopulation030232 urology & nephrology1842glomerular diseaseHIV InfectionsDiseaseacute renal failure03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)EpidemiologymedicinePrevalenceHumansCumulative incidence030212 general & internal medicine1506educationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryhospitalisationIncidence (epidemiology)IncidenceResearchHIVGeneral MedicineMiddle Agedmedicine.diseaseHospitalizationHIV/AIDSObservational studyFemaleKidney DiseasesFrancebusinessKidney diseaseBMJ open
researchProduct

The value of open-source clinical science in pandemic response

2021

International audience

Biomedical Research[SDV]Life Sciences [q-bio]Clinical scienceGlobal HealthCorrectionsMicrobiology1117 Public Health and Health Services1108 Medical MicrobiologyPandemicEconomicsHumansISARIC Clinical Characterisation GroupPandemicsCOVID-19/epidemiologyActuarial scienceInformation DisseminationSARS-CoV-2CommentISARICCOVID-191103 Clinical SciencesCommunicable Disease Control/methodsInfectious DiseasesOpen sourceCommunicable Disease ControlCOVID-19; Communicable Disease Control; Global Health; Humans; SARS-CoV-2; Biomedical Research; Information Dissemination; PandemicsValue (mathematics)HumanThe Lancet Infectious Diseases
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct

Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France.

2015

Équipe UB/CHU (EA) Pôle MERS CT3 Hors Enjeu; International audience; Background & AimsTo better evaluate the HIV-HCV co-infection burden in the context of new effective HCV treatment. MethodsWe reviewed all the epidemiological data available on HCV-related disease in HIV-infected patients in France. Sources of data have been selected using the following criteria: (i) prospective cohorts or cross-sectional surveys; (ii) conducted at a national level; (iii) in the HIV-infected population; (iv) able to identify HCV co-infection and chronic active hepatitis C (HCV RNA positive); and (v) conducted during the period 2003-2012. ResultsThe overall prevalence of HIV-HCV co-infection has decreased fr…

[SDE] Environmental SciencesMalemedicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationContext (language use)HIV InfectionsDiseaseHistory 21st CenturyMen who have sex with menDrug Users03 medical and health sciences0302 clinical medicineInternal medicineAntiretroviral Therapy Highly ActiveEpidemiologyGenotypemedicinePrevalence[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyHumans[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHomosexuality Maleeducationeducation.field_of_studyHepatologybusiness.industryCoinfectionvirus diseasesHIVHepatitis Cmedicine.diseaseHepatitis C3. Good health[SDV] Life Sciences [q-bio]ImmunologyHCV[SDE]Environmental Sciences030211 gastroenterology & hepatologyepidemiologyFrancebusinessViral loadLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients

2013

Abstract Background Even though it has been suggested that antiretroviral therapy has an impact on severe hypovitaminosis D (SHD) in HIV infected patients, it could be speculated that the different levels of residual inflammation on HAART (Highly Active Anti Retroviral Therapy) could contribute to SHD and aggravate bone catabolism in these patients. Methods A cross-sectional study was carried out in an unselected cohort of 263 HIV infected outpatients consulting during Spring 2010. Clinical examinations were performed and medical history, food habits, sun exposure and addictions were collected. Fasting blood samples were taken for immunological, virological, inflammation, endocrine and bone…

MaleHIV InfectionsGastroenterologyBone remodeling0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAntiretroviral Therapy Highly Active030212 general & internal medicineYoung adult0303 health sciencesUnivariate analysisHepatitis CMiddle Aged25-hydroxyvitamin D3. Good healthAntiretroviral therapy[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInfectious DiseasesCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemalemedicine.symptomInflammation MediatorsResearch ArticleAdultmedicine.medical_specialtyBone metabolismantiretroviral therapy;bone metabolism;HIV;inflammation;25-hydroxyvitamin DInflammationvitamin D deficiencyBone and Boneslcsh:Infectious and parasitic diseases03 medical and health sciencesYoung AdultInternal medicinemedicineHumansMedical historylcsh:RC109-216AgedInflammation030306 microbiologybusiness.industryHIVmedicine.diseaseVitamin D DeficiencyImmunologybusinessBiomarkersBMC Infectious Diseases
researchProduct

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

2021

Highlights • Antibiotics were a main part of COVID-19 treatments during the first epidemic peak. • Bacterial coinfections seem to be rare, especially if no ICU transfer needed. • We studied the place of antibiotics and the impact on prognosis of patients. • Antibiotics were prescribed if more severe infection and has no impact on prognosis. • We think that antibiotic therapy must be not widely prescribed.

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsInfectious and parasitic diseasesRC109-216Articlelaw.inventionHospitals University03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineHumans030212 general & internal medicineMedical prescriptionPropensity ScoreAgedAged 80 and overUnivariate analysisbusiness.industrySARS-CoV-2Hazard ratioCOVID-19General MedicineMiddle AgedAntibiotic therapyPrognosisIntensive care unitConfidence intervalAnti-Bacterial AgentsCOVID-19 Drug TreatmentHospitalizationInfectious DiseasesRadiological weaponSARS-CoV2Propensity score matchingFemaleFrancebusinessInternational Journal of Infectious Diseases
researchProduct

Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia

2019

International audience; Objectives - Time to blood culture positivity (TTP), a routinely available parameter in automated blood culture systems, may be a proxy for infectious burden in patients with bloodstream infections. We aimed to study the association between TTP and infective endocarditis (IE), or death, in patients with Staphylococcus aureus bacteraemia. Methods - VIRSTA is a multicenter prospective cohort study that included all adult patients with S. aureus bacteraemia in eight university hospitals in France (2009-2011). We analyzed data from four centers which collected data on TTP. Regression models were used to study the association between TTP and definite IE (Duke-Li criteria)…

MaleMethicillin-Resistant Staphylococcus aureus0301 basic medicineMicrobiology (medical)Staphylococcus aureusbacteraemiamedicine.medical_specialtyTime FactorsMultivariate analysis030106 microbiologyBacteremiaIndependent predictormedicine.disease_cause03 medical and health sciences0302 clinical medicineInterquartile rangehemic and lymphatic diseasesInternal medicinemedicineHumansBlood cultureProspective Studies030212 general & internal medicinetime to blood culture positivityProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedmedicine.diagnostic_testinfective endocarditisbusiness.industryEndocarditis BacterialGeneral MedicineMiddle AgedStaphylococcal Infectionsrespiratory systemmedicine.diseasemortality3. Good health[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesQuartileBlood CultureStaphylococcus aureusInfective endocarditisFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyClinical Microbiology and Infection
researchProduct

Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study.

2013

Background Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed. Methods An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011. Results Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 …

MalePathologymedicine.medical_specialtyAntibiotic susceptibilitymedicine.drug_classEpidemiologyAntibioticsCephalosporinResistanceContext (language use)Microbial Sensitivity TestsPeritonitisAmoxicillin-Potassium Clavulanate CombinationAntibiotic resistanceMedical microbiologySpontaneous bacterial peritonitisAnti-Infective Agents[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyEpidemiologyDrug Resistance BacterialmedicineEscherichia coliSpontaneous bacterial peritonitisAscitic FluidHumans[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedCross Infection[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBacterial InfectionsMiddle AgedAntimicrobialmedicine.disease3. Good healthAnti-Bacterial AgentsTreatment Outcome[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesBacterascitesFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Article
researchProduct

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

ESSAI RANDOMISÉ POUR ÉVALUER L’EFFICACITÉ ET LA SÉCURITÉ DE TRAITEMENTS CHEZ DES PATIENTS AMBULATOIRES ATTEINTS DE COVID-19 AYANT DES FACTEURS DE RIS…

2021

Context. The Covid-19 pandemic is of unprecedented magnitude and has had major social and health consequences. Primary care professionals, mainly general practitioners, ensure the care of most patients with Covid-19. An early-stage treatment administered to patients with risk factors for developing a severe disease could reduce hospitalization and death rates. No treatment is currently validated in this indication. Objectives. To evaluate the safety and efficacy of experimental candidate agents delivered in outpatient settings to reduce the risk of hospitalization or death in at-risk patients with early-stage proven Covid-19 and no indication for hospital admission. Methods. Multicentric, o…

treatment[SDV]Life Sciences [q-bio]protocolstrialInternalcontrolledclinical[SDV] Life Sciences [q-bio]earlyrandomizedoutpatientMedicineGeneralCovid-19
researchProduct

Mechanical ventilation and Streptococcus pneumoniae pneumonia alter mitochondrial homeostasis.

2018

Abstract Required mechanical ventilation (MV) may contribute to bacterial dissemination in patients with Streptococcus pneumoniae pneumonia. Significant variations in plasma mitochondrial DNA (mtDNA) have been reported in sepsis according to the outcome. The impact of lung stretch during MV was addressed in a model of pneumonia. Healthy or S. pneumoniae infected rabbits were submitted to MV or kept spontaneously breathing (SB). Bacterial burden, cytokines release, mitochondrial DNA levels, integrity and transcription were assessed along with 48-hour mortality. Compared with infected SB rabbits, MV rabbits developed more severe pneumonia with greater concentrations of bacteria in the lungs, …

InflammationMaleddc:617Tumor Necrosis Factor-alphalcsh:RInterleukin-1betaInterleukin-8lcsh:MedicinePneumoniaDNA MitochondrialRespiration ArtificialArticleInterleukin-10Adenosine TriphosphateStreptococcus pneumoniaeAnimalslcsh:QRNA MessengerRabbitslcsh:ScienceLungSpleenScientific reports
researchProduct

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

2022

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing como…

EğitimSocial Sciences and HumanitiesInformation Security and ReliabilitySocial Sciences (SOC)Sosyal Bilimler ve Beşeri BilimlerEpidemiologyEDUCATION & EDUCATIONAL RESEARCHTemel Bilimler (SCI)BİLGİSAYAR BİLİMİ BİLGİ SİSTEMLERİMATHEMATICSSociology[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesProspective StudiesCOMPUTER SCIENCE INFORMATION SYSTEMSSTATISTICS & PROBABILITYMatematikBilgisayar Bilimi UygulamalarıComputer SciencesBilgi Güvenliği ve GüvenilirliğiEĞİTİM VE EĞİTİM ARAŞTIRMASIBİLGİ BİLİMİ VE KÜTÜPHANE BİLİMİBilgi sistemiComputer Science ApplicationsKütüphane ve Bilgi BilimleriHospitalizationNatural Sciences (SCI)Physical SciencesEngineering and TechnologySosyal Bilimler (SOC)Bilgisayar BilimiStatistics Probability and UncertaintyInformation SystemsHumanStatistics and ProbabilityHumans; Pandemics; Prospective Studies; SARS-CoV-2; COVID-19; HospitalizationSOCIAL SCIENCES GENERALLibrary and Information SciencesEducationSDG 3 - Good Health and Well-beingLibrary SciencesINFORMATION SCIENCE & LIBRARY SCIENCEİstatistik ve OlasılıkHumansSosyal ve Beşeri BilimlerBilgisayar BilimleriSocial Sciences & HumanitiesEngineering Computing & Technology (ENG)SosyolojiPandemicsPandemicSARS-CoV-2İSTATİSTİK & OLASILIKCOVID-19Mühendislik Bilişim ve Teknoloji (ENG)İstatistik Olasılık ve BelirsizlikSosyal Bilimler GenelCOMPUTER SCIENCEProspective StudieFizik BilimleriViral infectionMühendislik ve TeknolojiKütüphanecilik
researchProduct

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a …

2022

Invasive mechanical ventilation; COVID-19; Critical care Ventilación mecánica invasiva; COVID-19; Cuidado crítico Ventilació mecànica invasiva; COVID-19; Atenció crítica Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multin…

:enfermedades respiratorias::trastornos respiratorios::insuficiencia respiratoria [ENFERMEDADES]COVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilationRespiració artificialCritical Care and Intensive Care Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractCOVID-19 (Malaltia) - Tractament[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCOVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilation; Humans; Prospective Studies; SARS-CoV-2; Tachypnea; COVID-19; Respiratory Insufficiency:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]HumansProspective StudiesInvasive mechanical ventilation:Otros calificadores::/terapia [Otros calificadores]TachypneaInsuficiència respiratòria - TractamentSARS-CoV-2:Therapeutics::Therapeutics::Respiratory Therapy::Respiration Artificial::Noninvasive Ventilation [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Other subheadings::/therapy [Other subheadings]:terapéutica::terapéutica::terapia respiratoria::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Respiratory Tract Diseases::Respiration Disorders::Respiratory Insufficiency [DISEASES]High flow nasal cannulaProspective StudieCritical careRespiratory InsufficiencyHumanCritical Care
researchProduct

Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with external ventricular drain

2018

International audience; Background: Due to its antibacterial properties ceftaroline could be attractive for the treatment of bacterial postneurosurgicalmeningitis. However only few data are available concerning its meningeal concentrations. The aim of this studywas to investigate ceftaroline cerebrospinal fluid (CSF) pharmacokinetics (PK) in intensive care unit (ICU) patients with anexternal ventricular drain (EVD).Materials/methods: Patients received a single 600 mg dose of ceftaroline as a one-hour intravenous infusion . Blood and CSFsamples were collected before and 0.5, 1, 3, 6, 12 and 24 hours after the end of the infusion. Concentrations were assayed inplasma and CSF by LC-MS/MS. A tw…

[SDV] Life Sciences [q-bio][SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesICU patients[SDV]Life Sciences [q-bio]ceftaroline[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencespharmacokineticscerebrospinal fluid
researchProduct

Association of country income level with the characteristics and outcomes of critically ill patients hospitalized with acute kidney injury and COVID-…

2023

Introduction Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results Among patients with COVID-19 ad…

acute kidney injurycovid-19NephrologyKidney International Reports
researchProduct